Karen Beatriz Méndez-Rodríguez, Luis Manuel Ramírez-Gómez, César Arturo Ilizaliturri Hernández, Jaime Antonio Borjas-García, Kelvin Saldaña-Villanueva, Francisco Javier Pérez-Vázquez
{"title":"Application of volatilomic analysis by electronic nose for the detection of women with preeclampsia at high risk of developing chronic kidney disease.","authors":"Karen Beatriz Méndez-Rodríguez, Luis Manuel Ramírez-Gómez, César Arturo Ilizaliturri Hernández, Jaime Antonio Borjas-García, Kelvin Saldaña-Villanueva, Francisco Javier Pérez-Vázquez","doi":"10.1016/j.cca.2025.120205","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Pre-eclampsia is a systemic disorder of pregnancy. Nowadays, there is no single clinical tool to identify women at risk of developing CKD after pre-eclampsia. The objective of this study was to create a statistical predictive model for chronic kidney disease (CKD) risk screening in patients with pre-eclampsia and persistent albuminuria by detecting global metabolite patterns in urine through the Cyranose® 320 electronic nose.</p><p><strong>Methods: </strong>The study included 22 pregnant women without risk factors for pre-eclampsia, 25 pregnant women with risk factors for pre-eclampsia, and 25 patients with diagnostic criteria for pre-eclampsia and 23 with CKD at the time of the study. There were analyzed urine samples by an electronic nose.</p><p><strong>Results: </strong>A natural variation between the study groups was verified through a PERMANOVA with a significant difference (F = 6.37, p < 0.0003). The statistical predictive model, performed through a Canonical analysis of principal coordinated (CAP), allowed correct classification of 68.4 % between all groups with a statistically significant difference (p = 0.0001). This study achieved discrimination between groups based on the metabolomic pattern present in urine.</p><p><strong>Conclusions: </strong>The generated model can be a potential tool in the timely detection of patients with preeclampsia who are at high risk of developing chronic kidney disease.</p>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":" ","pages":"120205"},"PeriodicalIF":3.2000,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Chimica Acta","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.cca.2025.120205","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Pre-eclampsia is a systemic disorder of pregnancy. Nowadays, there is no single clinical tool to identify women at risk of developing CKD after pre-eclampsia. The objective of this study was to create a statistical predictive model for chronic kidney disease (CKD) risk screening in patients with pre-eclampsia and persistent albuminuria by detecting global metabolite patterns in urine through the Cyranose® 320 electronic nose.
Methods: The study included 22 pregnant women without risk factors for pre-eclampsia, 25 pregnant women with risk factors for pre-eclampsia, and 25 patients with diagnostic criteria for pre-eclampsia and 23 with CKD at the time of the study. There were analyzed urine samples by an electronic nose.
Results: A natural variation between the study groups was verified through a PERMANOVA with a significant difference (F = 6.37, p < 0.0003). The statistical predictive model, performed through a Canonical analysis of principal coordinated (CAP), allowed correct classification of 68.4 % between all groups with a statistically significant difference (p = 0.0001). This study achieved discrimination between groups based on the metabolomic pattern present in urine.
Conclusions: The generated model can be a potential tool in the timely detection of patients with preeclampsia who are at high risk of developing chronic kidney disease.
期刊介绍：
The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)
Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells.
The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
